On May 26, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts demonstrate NeoGenomics’ expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD). These findings include an online presentation on the utilization of RaDaR ST in a colorectal cancer cohort, as reflected in an interim analysis from a collaboration with investigators at MD Anderson Cancer Center.

To support biopharma partners advancing ADCs, BiTES, bispecifics, radioligands, and targeted therapies, NeoGenomics will highlight new biomarkers, including B7-H3, CD137, EZH2, and PRMT5. The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited.

NeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient. Both will be reflected throughout the booth, alongside the company’s new tagline, ‘Answers are in our DNA.’

"A cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from first diagnosis through recurrence monitoring," said Tony Zook, CEO of NeoGenomics. "The breadth of our ASCO (Free ASCO Whitepaper) research and a sharpened mission reflect our commitment to providing personalized answers for every cancer patient."

Presentations and online abstracts at ASCO (Free ASCO Whitepaper) include:

Poster #177: Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing
Session: Quality Care/Health Services Research
Monday, June 1, 9 AM to 12 PM CDT | Hall A
Poster #337: From Infancy to Young Adulthood: Exploring the divergent genomic mechanisms that drive AML
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Monday, June 1, 9 AM to 12 PM CDT | Hall A
Poster #129a: Interception of Molecular Relapse in Breast Cancer: The SURVIVE HERoes Study (NCT06643585)
Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
Poster #135a: The SURVIVE Study: Re-evaluating Follow-up in Early Breast Cancer
Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
Online Abstract: Concordance of liquid biopsy and tissue CGP for identification of guideline-recommended actionable variants
Online Abstract: Real-world evidence for comprehensive genomic profiling in myeloid malignancies: changes in detection and clinical impact
Online Abstract: Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center
Online Abstract: Clinical actionability and molecular landscapes of fusion-driven sarcomas: A multi-modal integration analysis of comprehensive genomic profiling, targeted RNA-sequencing, and PD-L1 expression

(Press release, NeoGenomics Laboratories, MAY 26, 2026, View Source [SID1234666076])